Company profile
CORVUS PHARMACEUTICALS, INC.
NASDAQ:CRVSBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MUPADOLIMAB | phase3 | — | 3 | completed, terminated |
| SOQUELITINIB | phase3 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03952078 | phase1 | active_not_recruiting | 2019-05-03 | 2026-04-30 | Corvus Pharmaceuticals, Inc. | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma |
| NCT03454451 | phase1 | completed | 2018-04-25 | 2022-12-28 | Corvus Pharmaceuticals, Inc. | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers |
| NCT04734873 | phase3 | terminated | 2021-02-25 | 2021-08-18 | Corvus Pharmaceuticals, Inc. | CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients |
| NCT02655822 | phase1 | completed | 2016-01-01 | 2021-06-01 | Corvus Pharmaceuticals, Inc. | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers |
| NCT07828860 | phase1 | recruiting | 2026-09-17 | 2027-12-01 | Corvus Pharmaceuticals, Inc. | Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa |
FDA applications (0)
No records yet.